NDRA News & Events

"Over the past year we significantly strengthened the clinical foundation for TAEUS, demonstrating performance that we believe positions our technology alongside the current standard of care, while maintaining the accessibility, scalability and cost of handheld ultrasound systems," said Alexander Tokman, ENDRA's Chief Executive Officer. "We remain highly confident in the long-term potential of TAEUS and are optimistic about the value it can deliver to patients, clinicians and our shareholders. As we evaluate strategic alternatives for the company, our focus is on ensuring that this progress translates into maximum benefit for all stakeholders."

ENDRA Life Sciences' Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company.ENDRA has engaged Lucid Capital Management as its financial advisor and K&L Gates as its legal counsel in connection with this process. "The Board and management are committed to identifying and evaluating opportunities that may maximize the shareholder value while building on the progress we've made advancing ENDRA's strategic priorities," said Alexander Tokman, CEO. "We believe this process will help us assess a range of options available to the Company and determine the most appropriate path forward for ENDRA and its shareholders.

Endra Life Sciences announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS Liver device. "While MRI-PDFF remains the gold standard for liver fat quantification, its high cost and limited availability create significant barriers for the more than two billion people afflicted by MASLD," said Alexander Tokman, CEO of Endra Life Sciences. "These new performance data showing a 3.3% SEM and a 0.89 ICC strongly support our belief that TAEUS can deliver consistent results similar to an MRI, but at the point of patient care and at a much lower cost. This addresses a critical need for clinicians and pharmaceutical companies that require a diagnostic tool to monitor treatment frequently and affordably."

Endra Life Sciences announced new results from its 2025 Taeus Liver device feasibility study demonstrating that Taeus' thermo-acoustic fat fraction measurement closely tracks the MRI-PDFF standard at critical liver fat fraction thresholds of 12%-17% and 20%-22%. The company said, "These thresholds separate mild, moderate and severe disease, are widely used to make clinical therapy decisions in routine practice and are important for enrolling patients in clinical trials. The high accuracy of TAEUS at these specific points strengthens its potential as a practical, low-cost tool for the booming MASLD/MASH and obesity drug development landscape. In the recently completed feasibility study of 40 subjects with BMI ranging from 21 to 47, ENDRA evaluated the performance of its TAFF biomarker test against MRI-PDFF at decision thresholds that segment patients from mild to moderate-to-severe steatosis."